The FDA approved the New Drug Application (NDA) for cocaine hydrochloride nasal solution 4% (40 mg/ml) (Numbrino, Lannett Co., Inc.), a local anesthetic indicated for use in diagnostic procedures and surgeries in adults.
“We believe the product has the potential to be an excellent option for the labeled indication,” said Tim Crew, the CEO of Lannett.
JANUARY 14, 2020